Our approach enhances brain remodeling and plasticity by administering neurogenesis-promoting drugs directly into the brains of patients. Our lead program aims to improve brain and motor function in victims of stroke. ReNeu was formed as a joint venture: our technology combines the clinically advanced neurogenesis-promoting drugs developed by Stem Cell Therapeutics (TSX:SSS) with the FDA-cleared intracranial delivery systems of NexGen Medical.